Cargando…
Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study
In this retrospective cohort study, we evaluated the efficacy of baricitinib in the treatment of coronavirus disease 2019 (COVID-19). Among 404 adult patients with COVID-19 who were admitted to our hospital between October 23, 2020, and July 31, 2021, 229 patients with respiratory failure were inclu...
Autores principales: | Tanimoto, Takuya, Tada, Shinpei, Fujita, Suguru, Hirakawa, Tetsu, Matsumura, Mirai, Isoyama, Shoko, Ueno, Sayaka, Hamai, Kosuke, Tsuji, Naoki, Hirosawa, Hideyasu, Taniguchi, Tomohiro, Okamoto, Takeshi, Omoto, Takuji, Kusunoki, Shinji, Maeda, Hiroyuki, Ishikawa, Nobuhisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Respiratory Society. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898743/ https://www.ncbi.nlm.nih.gov/pubmed/35307364 http://dx.doi.org/10.1016/j.resinv.2022.02.004 |
Ejemplares similares
-
Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
por: Hamai, Kosuke, et al.
Publicado: (2023) -
Need for a high-specificity test for confirming weakly positive result in an immunochromatographic SARS-CoV-2-specific antigen test: A case report
por: Tanimoto, Takuya, et al.
Publicado: (2021) -
First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report
por: Hamai, Kosuke, et al.
Publicado: (2020) -
Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
por: Isoyama, Shoko, et al.
Publicado: (2022) -
Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high PD‐L1
por: Masuda, Takeshi, et al.
Publicado: (2022)